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Available online 21 February 2017AbstractA bacterial biofilm is a structured community of bacteria in a self-produced extracellular matrix, adherent to an inert surface or biological
tissue. The involvement of biofilm in a bacterial infection implies that the infection is difficult to treat and that the patient will probably
experience relapses of the condition. In bacterial vaginosis (BV), the lactobacilli concentration decreases, while the bacterial load of other
(facultative) anaerobic bacteria increases. A hallmark of BV is the presence of clue cells, now known as the result of a polymicrobial biofilm
formed in vaginal epithelial cells. Current knowledge of the individual roles of bacterial species involved in polymicrobial BV biofilms or
interactions between these species are not fully known. In addition, knowledge of the composition matrix and triggers of biofilm formation is
still lacking. Bacteria are able to attach to the surface of indwelling medical devices and cover these surfaces with biofilm. Vaginally inserted
devices, such as tampons, intra-uterine devices and vaginal rings, can also be colonized by bacteria and be subjected to biofilm formation. This
might hamper release of active product in case of drug-releasing devices such as vaginal rings, or promote the presence of unfavorable bacteria
in the vagina. This paper reviews current knowledge of biofilms in the vaginal environment.
© 2017 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
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A bacterial biofilm is a structured community of bacteria
that is adherent to an inert surface or biological tissue. The
biofilm is enclosed in a mucous substance: a self-produced
matrix of extracellular polymeric substances (EPS) [1]. This
community is often characterized by a complex internal ar-
chitecture and contains channels allowing circulation of nu-
trients [2]. Separate areas in the biofilm can contain
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adverse conditions and better persistence in hostile environ-
ments. It offers protection against chemical disinfection,
antimicrobial treatment and human immune responses [1].1.1. Bacterial biofilm infectionsBiofilm infections share clinical characteristics, regardless
of in site in the human body where the biofilm develops.
Biofilms grow slowly and symptoms usually appear gradually
[4]. Biofilm communities are rarely fully eradicated by the
host defense mechanisms. Sessile bacterial biofilm cells
release antigens resulting in increased antibody production.
However, due to the biofilm structure, the produced antibodies
are not capable of killing the biofilm bacteria and accumulate
in the surrounding tissues. This can result in immune-
complex-related damage to the same tissues [5]. The biofilmreserved.
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bial granule contents and reactive oxygen species that promote
collagen degradation and subsequent host tissue injury [6]. On
top of that, as antibiotic therapy fails to eradicate all bacteria
in the biofilm, only the symptoms caused by the dispersed
biofilm bacteria are reversed after treatment [1]. As a result,
even after multiple cycles of antibiotic therapy, biofilm in-
fections are characterized by relapses of the condition [3]. In
summary, bacterial biofilm causes persistent, slowly-
progressing and chronic infections.1.2. Stages in the biofilm life cycleBiofilm formation is facilitated by a regulated switch be-
tween the planktonic lifestyle of single (motile) cells and the
multicellular aggregated sedentary state of bacteria. The bio-
film life cycle includes: attachment to a substrate, production
of EPS, development of a mature biofilm structure and
dispersal by detachment of aggregates or by release of single
dispersed cells (Fig. 1).Fig. 1. The biofilm cycle. Biofilm develops on surfaces such as the epithelium and is
which leads to colonization of this surface. After attracting more bacteria, a mature
this biofilm to return to the free-living state or to start over on another surface.After first colonization of a surface, bacteria organize into
complex multicellular clusters or microcolonies (5e200 mm
wide) [7]. They produce EPS, which forms a matrix wherein
bacteria are held together and which allows them to develop a
three-dimensional structure [7]. This biofilm grows slowly
through a combination of cell division and recruitment of
other bacteria. Bacterial cells in the biofilm can remain
dormant or inactive until the circumstances are favorable for
them to start growing, and this results in clinical infections [8].
Within biofilms, gradients of pH, nutrients and oxygen can be
found. For example, due to the consumption of oxygen by
aerobic biofilm-associated bacteria, an oxygen gradient de-
velops with increasing anaerobic conditions towards the inner
stratum or core [7].
When the biofilm increases, the inner cells become sepa-
rated from the bulk liquid interface at the outside of the bio-
film, where most essential sources of energy and nutrients are
stored. In addition, waste products and toxins accumulate in
the growing biofilm, which can be detrimental to cell survival.
Biofilm cells can escape the sessile growth mode for self-typically formed in four stages. First, free-living bacteria adhere to the surface,
biofilm is formed when the conditions are favorable and bacteria disperse from
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infections. They may detach from the biofilm structure indi-
vidually or disperse in aggregates while retaining the biofilm
organization [9].1.3. The biofilm matrixThe biofilm matrix determines the immediate living con-
ditions of the bacteria by affecting porosity, density, water
content, charge, sorption properties, hydrophobicity and me-
chanical stability [10]. The composition of the biofilm matrix
is highly variable, not only between different species, but also
between different strains, and is highly dependent on sur-
rounding environmental conditions [11]. Exopolysaccharides
are an important part of the extracellular matrix that addi-
tionally comprises a range of biopolymers such as proteins,
glycoproteins, glycolipids and extracellular DNA [12].1.4. Increased antibiotic resistance and tolerance of
biofilm cellsBiofilms are characterized by decreased susceptibility to
antimicrobial agents. Next to the known mechanisms of bacte-
rial resistance [13], treatment of biofilm-related illness is chal-
lenging due the specific architecture of this biofilm. First of all,
the applied antibiotics can be pumped out of the biofilm or can
be degraded by the active bacteria in the outer biofilm sub-
population [14]. Furthermore, the biofilmmatrix forms a barrier
against all antibiotics, even though this is not completely
impermeable (as demonstrated by mathematical models [15]
and experimentally for some antibiotics [16]). Relatively large
antibiotic compounds may be constrained by the viscous matrix
and be slowed down, resulting in decreased penetration in the
biofilm [17]. The matrix components can also chemically
neutralize antimicrobial compounds [18]. Other biofilm-
environment-related factors, such as differences in pH, pCO2
or pO2, may further affect the efficacy of the antimicrobials
[19,20]. Due to the existence of several bacteria layers in the
biofilm, nutrients and oxygen are depleted in the biofilm core.
This nutrition and oxygen gradient slows down the growth and
metabolism of bacteria in the inner stratum of the biofilm
[21e23]. The subpopulation of bacteria residing in the biofilm
core is a group of dormant bacteria, and their presence can be
influenced by the biofilm growth conditions [24,25]. When
exposed to antibiotics, some of the dormant bacteria acquire
increased tolerance towards antibiotics without undergoing
genetic changes, and are known as ‘persisters’ [26]. In 1942,
Hobby et al. [27] discovered that 1% of Staphylococcus aureus
cells were not killed by penicillin. As such, persister cells can
lead to relapses after treatment: when the concentration of
antibiotic compounds drops, the persister cells revert to their
phenotype, causing re-growth of the biofilm [28].1.5. Communication between bacteriaCommunication between neighboring bacterial cells occurs
through quorum sensing. It allows bacteria to monitor theenvironment for other bacteria and alter their behavior in
response to changes in the number of cells (quorum) and/or
species present in the community. The communication process
requires the production and constitutive release of small
hormone-like chemical signaling molecules called auto-
inducers. The concentration of released auto-inducers in-
creases as a function of cell density. Above a certain threshold,
it will trigger an alteration in the expression profile of the
individual cells [29]. Consequently, bacterial biofilms can act
as multicellular organisms with different gene expression
patterns among genetically identical cells [30].
Due to the spatial heterogeneity and biodiversity in mixed-
species biofilms, the “calling distance” can be an important
factor in quorum sensing. Egland et al. [31] demonstrated that
signaling occurred mainly within cell clusters, rather than
across them. Therefore, it is suggested that the distance be-
tween bacteria may be more important than the number of
cells present. Thus, auto-inducer accumulation may be
dependent not only on population density, but also on cell
proximity [32].1.6. Multispecies biofilmsMost bacteria live within a multispecies biofilm, interacting
with cells of the other species. These interspecific interactions
can be antagonistic or synergistic, and include communication
via quorum sensing. Synergistic interactions results in the
optimization of living conditions in biofilms, for example,
through metabolic collaboration between bacteria where one
species utilizes a metabolite that was produced by a neigh-
boring species [33], or through the establishment of an oxygen
gradient allowing anaerobic bacteria to survive in the biofilm
[7,34,35]. An example of a multispecies vaginal biofilm is the
biofilm involved in bacterial vaginosis (BV) [36], which is
discussed in the next section.
2. Biofilm associated with bacterial vaginosis2.1. Bacterial vaginosisA healthy vaginal microbiome can be defined as a vaginal
environment in which infections or symptoms are absent and
that is associated with good reproductive health outcome [37].
Furthermore, the healthy vaginal microbiome is typically
dominated by a limited number of different Lactobacillus
species (Fig. 2), whereas BV is a polybacterial dysbiosis
(Fig. 3). The lactobacilli concentration (with the exception of
Lactobacillus iners) decreases during BV, while the bacterial
load of other (facultative) anaerobic bacteria, such as Gard-
nerella vaginalis, Atopobium vaginae, Prevotella spp., Snea-
thia spp. and many others increases [38,39].2.2. Biofilm in bacterial vaginosisThe ability of G. vaginalis, probably the most prevalent and
abundant species in BV, to colonize human cells was already
established in the eighties [40,41]. In fact, the presence of
Fig. 2. Lactobacillus-dominated vaginal microbiome. The health-associated vaginal microbiome is supported by the availability of glycogen, that acts as a carbon
source for Lactobacillus species that maintain the low vaginal pH which exerts selective antimicrobial activity. Lactobacilli also produce bacteriocins and compete
for receptor sites on the vaginal epithelium with non-advantageous and pathogenic species.
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characteristic cells that provide a clue to recognizing BV), is
one of the Amsel criteria used in clinical settings to diagnose
the condition. Such coating of epithelial cells with multiple
layers of bacteria is exactly what one expects to see in case of
biofilm formation. In reality, we have been looking at clue
cells for decades, without realizing that we were dealing with
biofilm formation. However, it was not until 2005 that Swid-
sinski and colleagues [36] demonstrated the presence of this
polymicrobial biofilm adhering to the vaginal epithelial cells
in BV, using fluorescence in situ hybridization (FISH). After
this first demonstration, other groups developed probes for
other associated bacteria to visualize microorganisms involved
in BV [42e44].Providing further evidence for the biofilm nature of BV, the
treatment of BV is very challenging due to recurrence and
relapses after antibiotic therapy, as is also the case in other
biofilm-associated infections. Little is known about the exact
mechanisms of biofilm formation in BV: the genes respon-
sible, communication strategies (quorum sensing, metabolic
communication) and genetic exchanges between biofilm-
associated bacteria. Although it has been established that BV
is a polymicrobial condition that involves a polymicrobial
biofilm, we do not know the importance of the separate
members nor the mechanisms of how these species interact.
As such, it is not clear whether all species found in the BV
biofilm have a role in pathogenesis, or are simply a conse-
quence of biofilm formation on the vaginal epithelium [45].
Fig. 3. Bacterial vaginosis-associated vaginal microbiome. In the dysbiosis-associated vaginal microbiome, beneficial lactobacilli are outnumbered by other micro-
aerophilic and anaerobic organisms. This is accompanied by a degradation of the mucus layer and disruption of the barrier function that results in increased
exposure to non-advantageous and pathogenic species and viral pathogens.
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vaginalis and other BV-associated bacteria [46]. G. vaginalis
is thought to be an important player in BV, even though it also
occurs in the healthy vaginal microbiome [47]. However,
genomic and microbiological data suggest the existence of
multiple lineages of G. vaginalis, among which presumably
not all strains will be able to cause BV [48e52].
The presence ofG. vaginalis in vaginal eubiosis as well as in
vaginal dysbiosis might be the result of a mere quantitative
difference, with many more cells of this species present in
dysbiosis [38], but qualitative differences might be evoked as
well. A possible explanation for this phenomenon may be
related to a lower capacity of initial adhesion to the vaginal
epithelium of a specific subset of G. vaginalis strains [53]. G.
vaginalis has multiple virulence factors that may contribute to
development of a biofilm. Specifically, the presence of fimbriae
[54] and the ability to produce sialidase [52,55e57], and vagi-
nolysin [58] could play a major role in the colonization of thevaginal epithelial cells, and its ability to produce EPS [54] could
be important in the maturation of the biofilm.
It is therefore tempting to consider G. vaginalis as the
initial colonizer that provides a scaffold to which other bac-
teria, secondary colonizers, attach in order to establish a
mature biofilm. One of these secondary colonizers is A.
vaginae [59], an obligate anaerobic species, that has been
linked to BV [60,61], and that, unlike G. vaginalis, is usually
not present in the health-related vaginal microbiome. The
detection of a vaginal biofilm with both G. vaginalis and A.
vaginae (Fig. 4) is associated with a higher probability of
having BV, as assessed by the Nugent criteria [59].2.3. Treatment of bacterial vaginosisCurrently available antibiotics used for oral or vaginal
treatment of BV (metronidazole, tinidazole and clindamycin)
have poor initial cure rates and high relapse rates in those who
Fig. 4. Superimposed fluorescence in situ hybridization image of poly-
microbial biofilm of Atopobium vaginae and Gardnerella vaginalis. Montage
of confocal laser scanning microscopy images with 400 magnification of
polymicrobial biofilm in a vaginal sample: vaginal epithelial cells DAPI in
blue, G. vaginalis specific PNA-probe Gard162 with Alexa Fluor 647 in red
and A. vaginae specific PNA-probe AtoITM1 with Alexa Fluor 488 in green.
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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treatment could possibly result in drug resistance in BV-
associated bacteria such as G. vaginalis, A. vaginae, Pre-
votella spp., Bacteroides spp. and Peptostreptococcus spp.
[64e67]. Alternatives for these ineffective antibiotic treat-
ments are increasingly being explored: antiseptics, disinfec-
tants, vaginal acidifying and buffering agents, combination
therapies, and vaginal and oral probiotics, but until now, none
has been found to be successful [68,69].
One possible approach to dealing with BV is the restoration
of the vaginal environment by the administration of live mi-
croorganisms, or probiotics [62,70e72], while other ap-
proaches try to tackle the biofilm. Strategies to destroy the
biofilm and treat BV could involve acidifying the vaginal
environment [73], application of synthetic antimicrobial pep-
tides [74], application of antiseptics [75] and plant-derived
compounds [76] and destruction of the biofilm matrix [77].
Combination therapies that combine disruption of the biofilm
matrix with specific bactericidal effects will likely be most
effective. For example, recent in vitro work by Gottschick
et al. [78] demonstrated that attacking the biofilm and the
bacterial cells by a combination of an amphoteric tenside so-
dium coco-amphoacetate and the antibiotic metronidazole
might be a useful strategy against BV. While the antibiotics
metronidazole and tobramycin were highly effective in pre-
venting biofilm formation, they could not destroy the estab-
lished biofilm, but co-administration of amphoteric tenside
increased the effect of metronidazole on reducing the biomass
by 40% and on viability by 61%.An approach that is still understudied is the use of bacte-
riophages in the treatment of BV, although a number of studies
using phages in other biofilm-associated infections have
already been carried out [79]. Phage therapy could provide a
natural, highly specific and safe approach controlling BV-
associated bacteria if the phages are able to reach the bio-
film in sufficient concentrations [80,81]. Controlled infection
with a mixture of bacteriophages would result in the lysis and
killing of specific targeted bacteria. The active penetration of
phages in the biofilm has an impact on the structure of biofilms
and promotes the release of new phage virions that will infect
adjacent bacteria [80,81]. Additionally, certain bacteriophages
can express EPS depolymerase enzymes [82,83] that
contribute to the degradation of the biofilm matrix and struc-
ture. However, currently, no bacteriophages for BV-associated
bacteria have been described, and the interactions of natural
bacteriophages with the matrix of the BV biofilm will also
need to be studied more extensively before this approach can
be taken into consideration.
And finally, another understudied approach to eradicating
BV biofilm would be an interaction with quorum sensing, or
cellecell communication. The potential of small chemical
compounds to interfere with the communication between
bacterial cells is being investigated [79,84]. However, there is
still little or no knowledge available on quorum sensing in BV
biofilm, let alone on how to interfere with it.
3. Bacterial biofilm on vaginal devices
Microorganisms are able to attach to the surface of
indwelling medical devices and cover these surfaces with
biofilm. For example, the most important reason to surgically
remove implanted prostheses is the development of biofilm
and associated infections at the implantation site [85,86].
Bacteria might also be able to attach to vaginally inserted
devices, but as yet, little information is available regarding this
topic.3.1. Bacterial biofilm on tamponsThe only study thus far looking into biofilm development
on tampon fibers focussed on S. aureus biofilm [87]. S. aureus
can cause a menstrual toxic shock syndrome through pro-
duction of toxin shock syndrome toxin (TSST-1). However,
only 10e20% of the S. aureus colonizing the vaginal tract
produce this toxin. It has been reported that the rate of colo-
nization is higher during menses [88]. The study used mo-
lecular amplification techniques to confirm the presence of S.
aureus in vaginal specimens and FISH to observe biofilm on
tampons and in vaginal wash specimens. Cell-adherent bac-
terial biofilm was observed in the vaginal wash specimens and
on tampon fibers from healthy menstruating women.3.2. Bacterial biofilm on intra-uterine devicesEvidence for biofilm formation on copper intra-uterine
devices (IUDs) has been demonstrated in a number of
Fig. 5. Visualization of biomass on an intravaginal ring surface by scanning electron microscopy at 1000 magnification: A) phenotype 1: elongated bacteria
scattered on vaginal epithelial cells; B) phenotype 2: condensed biofilm of bacilli on vaginal epithelial cells.
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and Micrococcus spp. have been isolated from removed IUDs
[89,90]. Shanmughapriya et al. confirmed previous observa-
tions of Actinomycetes spp. proliferating in the endocervix of
IUD users [91]. They showed in vitro that Nocardia spp. were
able to form biofilm on copper sheets. Also, Actinomyces
israelii was able to colonize copper IUDs [92]. Elsayed et al.
reported a case of IUD-associated pelvic actinomycosis due to
Actinomyces urogenitalis in a previously healthy young adult
woman [93]. A mixture of anaerobic bacteria was cultured
from a copper IUD removed after 10 years of use from a
woman presenting symptoms of pelvic inflammatory disease.
The scanning electron microscopy (SEM) picture of the IUD
showed a mature bacterial biofilm involving coccal and
bacillary forms on the IUD's surface [94].3.3. Bacterial biofilm on intravaginal ringsIntravaginal rings delivering hormones are being used in
the context of pregnancy prevention or estrogen replacement
therapy. However, few studies have investigated biofilm for-
mation on intravaginal rings in humans. Miller et al. [95]
examined a contraceptive vaginal ring (CVR), NuvaRing,
after four weeks of use by one healthy volunteer, and observed
only cellular debris, but no bacterial growth on the surface of
the ring using scanning electron microscopy, although this
may be due to a technical shortcoming, as they visualized the
ring surface only at very low magnification. A study in human
volunteers showed the presence of biomass on all 48 rings
containing an antiretroviral drug that were used for four weeks
[96]. In this population of women, among whom more than
two-thirds had a normal Nugent score, the ring biomass den-
sity (semi-quantified visually with SEM) was not associated
with the diagnosis of BV, according to Nugent [96].
A recent study among Rwandan women using the
NuvaRing® [97] clearly demonstrated the accumulation of
biomass consisting of vaginal epithelial cells and associated
bacteria, on intravaginal rings inserted for three weeks. The
higher the Nugent score in the women using the NuvaRing®,
the higher the biomass density, measured by crystal violet
staining. Furthermore, the density of the biomass was associ-
ated with the presence of a vaginal biofilm visualized using
FISH with peptide nucleic acid (PNA) probes specificallytargeting G. vaginalis and A. vaginae [97]. Lactobacilli were
also identified in the CVR biomass, but neither their presence
nor their concentration was correlated with the biomass den-
sity. Overall, the biomass consisted of vaginal epithelial cells
with bacterial species in the same ratio as those found in the
vaginal secretions of the women. Consequently, it was
concluded that the biomass on the vaginal rings mirrored the
vaginal microbiome of the women. SEM pictures of the CVRs
used showed two types of biomass structure. Fig. 5a shows an
accumulation of vaginal epithelial cells covered by a loose
structure of scattered elongated bacteria with a morphology
compatible with lactobacilli (type 1), whereas Fig. 5b dem-
onstrates vaginal epithelial cells coated by a dense structure of
coccobacillar bacteria, compatible with a biofilm structure
(type 2). The presence of type 2 biomass coincided with a
vaginal BV Nugent score above 7 and the presence of a
vaginal biofilm and of BV-associated bacteria present in the
vagina according to qPCR [97].
Other bacteria that are occasionally found in the vaginal
environment, such as the pathogen Neisseria gonorrhoeae,
have been shown in vitro to form biofilm on intravaginal rings
[98]. The ability of the gonococci to form biofilm was greater
on intravaginal rings that included silicone as compared to
thermoplastic ring material [98].
Only a limited number of studies on the formation of
biomass on intravaginal rings have been carried out. More
research still needs to be done on the impact of biomass and
biofilm on the vaginal microbiota and on the product release
properties of the vaginal delivery device.
4. Conclusions
Biofilm formed on vaginal epithelial cells is an important
process in the pathogenesis of bacterial vaginosis. Multispecies
biofilms associated with bacterial vaginosis have been visual-
ized. Knowledge of the composition of the in vivo extracelullar
matrix and triggers of biofilm formation such as quorum sensing
is still lacking. Research aimed at characterizing BV-associated
biofilm is required. This knowledge will lead to the design of
adequate treatments of BV that would prevent recurrence of the
condition. Additionally, more research is needed regarding the
formation of biofilm or biomass on vaginally inserted devices,
such as vaginal rings used for therapeutic or preventive
872 L. Hardy et al. / Research in Microbiology 168 (2017) 865e874purposes. Intravaginal rings are being investigated as delivery
systems for products for BV prevention, for example, by the
addition of lactic acid or for hormones, combined with anti-
microbial products, including antiretroviral drugs. The deposit
of biomass or formation of biofilm on these rings might hamper
the release of the active product or promote the presence of
unfavorable bacteria in the vagina, and should thus be consid-
ered when developing these products.
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